Importantly, various mutations that reduce TRAIL affinity to its receptors were previously reported [81] and enhanced clustering of TRAIL receptors at target cancer cells by dual targeting against epidermal growth factor receptor (EGFR) was also established [12,82] suggesting these could be viable future strategies to reduce TRAIL affinity and therefore increase its CNS-delivery. The gene discussed is EGFR; the disease is cancer.